Skip to main content
Clinical Trials/JPRN-UMIN000027010
JPRN-UMIN000027010
Recruiting
Phase 2

Allogeneic hematopoietic stem cell transplantation from HLA6/8-4/8 matched related donor for poor prognostic or refractory hematologic malignancy and solid tumor - Ibaraki Children's Hospital phase II study - ICH-HAPLO-16

Ibaraki Children's Hospital0 sites30 target enrollmentApril 17, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute leukemia, malignant lymphoma, and solid tumor
Sponsor
Ibaraki Children's Hospital
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 17, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ibaraki Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Germ line chromosomal abnormality other than trisomy 21 (2\)Concurrent or prior malignant disease other than the original disease in interest or prior organ transplantation other than hematopoietic cell transplantation (3\)Congenital or acquired immunodeficiency (4\)Uncontrolled fungal, bacterial, or viral infection (including tuberculosis of HIV) (5\)Pregnant, lactating, or highly suspected to be pregnant (6\)Corrected QT interval by Fridericia, more than 0\.45 second (7\)Active hemorrhage in central nervous system, fulfilling grade more than 3 on CTCAE version 4\.0 (8\)Consciousness disturbance, score less than 14 on Glasgow Coma Scale (9\)Obesity, by more than 30% of average weight for age. (10\)Considered to be unsuitable for entry for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials